Skip to main content
MindBio Therapeutics Corp. logo

MindBio Therapeutics Corp. — Investor Relations & Filings

Ticker · MBIO ISIN · CA60256C2076 CSE Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 113 across all filing types
Latest filing 2025-05-12 Capital/Financing Update
Country CA Canada
Listing CSE MBIO

About MindBio Therapeutics Corp.

https://mindbiotherapeutics.com/

MindBio Therapeutics Corp. develops and commercializes AI-powered health prediction technologies utilizing proprietary acoustic biomarkers extracted from the human voice. The company's core offering is a comprehensive enterprise platform designed for real-time intoxication and impairment detection, primarily focusing on sobriety verification in safety-critical environments. This platform employs machine learning algorithms to analyze over 140 acoustic parameters, such as jitter, shimmer, and spectral entropy, achieving greater than 88% prediction accuracy in under three seconds. Target markets include zero-tolerance industries like aviation, mining, and construction, requiring scalable, non-invasive fitness-for-duty verification. The technology transforms speech into actionable health intelligence for workforce monitoring and advanced telehealth applications.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 1% confidence The document is a corporate press release announcing a non-brokered private placement (issuing new common shares for gross proceeds of up to $110,000) and a debt settlement plan involving share issuances. It focuses entirely on fundraising and capital structure changes rather than operational, legal, or regulatory report content. This fits the definition of a Capital/Financing Update (CAP).
2025-05-12 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The text is a CEO/CFO certificate under Canadian NI 52-109 attesting to the interim financial and management reports for the quarter ended March 31, 2025. It contains no financial statements or management discussion—just the required regulatory attestation. This does not itself constitute the full interim report (IR) but is a standalone regulatory filing required under securities law. Therefore it falls into the general regulatory filings bucket (RNS).
2025-05-07 French
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 45-106F1 “Report of Exempt Distribution,” a mandatory securities regulatory filing detailing the distribution of common shares under a prospectus exemption. It is not an earnings announcement, management discussion, or investor presentation, nor is it a report publication notice. It does not fit into finance press releases (CAP) or share issue announcements (SHA) for investors, but rather is a prescribed regulatory disclosure under Canadian securities law. Therefore, it is classified as a general regulatory filing (RNS).
2025-05-03 English
52-109F1R - Certification of refiled annual filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a certification under Canadian NI 52-109 (Form 52-109F1R) by the CFO attesting to the refiled annual MD&A and financial statements. It is neither the annual report itself nor a management discussion, earnings release, proxy, dividend notice, or any other specific category. This type of compliance certificate is a regulatory filing that does not belong to any of the narrow categories above, so it defaults to Regulatory Filings (RNS).
2025-04-16 English
52-109F1R - Certification of refiled annual filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109F1R certification under Canadian NI 52-109, signed by the CEO to certify the refiled annual MD&A and financial statements. It is neither the annual report/MD&A itself nor an earnings release, but a compliance certification filing required by securities regulators. It does not fit any specific category for financial reports or announcements, so it falls under the fallback “Regulatory Filings” category (RNS).
2025-04-16 English
Annual MD&A (amended) - English.pdf
Management Reports Classification · 1% confidence The document is titled “Management’s Discussion & Analysis” for the years ended June 30, 2024 and 2023. It presents management’s detailed commentary on financial results, operations, trends, liquidity, capital resources, and outlook. It is not the full Annual Report nor an earnings release or a presentation, but specifically the MD&A section, matching the Management Reports category (MDA).
2025-04-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.